1 Ocak 2024 Dergi makalesi Açık Erişim

Cakmak, Sude Saral; Erdogan, Omer; Basoglu, Faika; Coruh, Ufuk; Cevik, Ozge; Karakus, Sevgi

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/283851</identifier>
  <creators>
    <creator>
      <creatorName>Cakmak, Sude Saral</creatorName>
      <givenName>Sude Saral</givenName>
      <familyName>Cakmak</familyName>
    </creator>
    <creator>
      <creatorName>Erdogan, Omer</creatorName>
      <givenName>Omer</givenName>
      <familyName>Erdogan</familyName>
      <affiliation>Gaziantep Islamic Sci &amp; Technol Univ, Sch Med, Dept Biochem, TR-27010 Gaziantep, Turkiye</affiliation>
    </creator>
    <creator>
      <creatorName>Basoglu, Faika</creatorName>
      <givenName>Faika</givenName>
      <familyName>Basoglu</familyName>
      <affiliation>European Univ Lefke, Fac Pharm, Dept Pharmaceut Chem, Northern Cyprus TR-10, Mersin, Turkiye</affiliation>
    </creator>
    <creator>
      <creatorName>Coruh, Ufuk</creatorName>
      <givenName>Ufuk</givenName>
      <familyName>Coruh</familyName>
      <affiliation>Ondokuz Mayis Univ, Fac Sci, Dept Phys, TR-55139 Samsun, Turkiye</affiliation>
    </creator>
    <creator>
      <creatorName>Cevik, Ozge</creatorName>
      <givenName>Ozge</givenName>
      <familyName>Cevik</familyName>
      <affiliation>Aydin Adnan Menderes Univ, Sch Med, Dept Biochem, TR-09010 Aydin, Turkiye</affiliation>
    </creator>
    <creator>
      <creatorName>Karakus, Sevgi</creatorName>
      <givenName>Sevgi</givenName>
      <familyName>Karakus</familyName>
      <affiliation>Istanbul Aydin Univ, Fac Pharm, Dept Pharmaceut Chem, TR-34295 Istanbul, Turkiye</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Exploring Etofenamate Hydrazide-Hydrazone/Copper(Ii) Complexes: Synthesis, Anticancer Activity, Carbonic Anhydrase Ix Inhibition And Docking Studies</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2024</publicationYear>
  <dates>
    <date dateType="Issued">2024-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/283851</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1016/j.molstruc.2024.138555</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;Hydrazide-hydrazone derivatives have garnered significant interest from researchers globally due to their wide range of biological activities, including antiviral, anticancer, and anti-inflammatory properties. In this study, a novel series of etofenamate hydrazide-hydrazone compounds (2a-2s) and their Cu(II) complexes (3a-3s) were designed and synthesized. The compounds were characterized using various analytical techniques such as FT-IR, 1H NMR, 13C NMR, MS, and elemental analysis. Additionally, the compound 2c and Cu(II) hydrazone complex 3a were further characterized using single X-ray crystallography. The anti-proliferative activity of the compounds was evaluated against Ishikawa human endometrial cancer cell line and non-tumour L929 cells using MTT assay. Additionally, the apoptotic potential of the compounds was investigated through caspase-3 activity, Bax and Bcl2 gene expression analysis, and annexin-V binding. Furthermore, carbonic anhydrase IX activity and in silico studies were conducted to elucidate the mechanism of action. Overall, compound 3s demonstrated significant antiproliferative effects with an IC50 value of 0.27 +/- 0.01 mu M against Ishikawa cells.&lt;/p&gt;</description>
  </descriptions>
</resource>